RecruitingNot ApplicableNCT05710211
Clonal Architecture of ASXL1-mutated Myelofibrosis
Sponsor
University Hospital, Angers
Enrollment
50 participants
Start Date
Apr 24, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Adults (age ≥18 years),
- Affiliated to the national social security system,
- ASXL1 mutated primary or secondary myelofibrosis,
- Signed the consent to participate in the study,
- Included, or consenting to be included, in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM).
Exclusion Criteria2
- Patient with another active hematological disease or cancer at the time of diagnosis,
- Person subject to legal protection scheme or incapable of giving consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALClonal architecture determination
Biological: * Determination of clonal architecture by sorting of circulating CD34 positive cells followed by cell culture and colony genotyping and/or single-cell DNA-sequencing * Secondary outcome: transcriptomic study by RNA-sequencing
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05710211
Related Trials
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT0532019824 locations
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT0417619884 locations
Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
NCT067810992 locations
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
NCT074808242 locations
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
NCT067731959 locations